Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SIBN

SI-BONE Inc

May 01 • 04:00PM ET

14.51

Dollar change +0.25
Percentage change 1.75	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IHI SCHA VTWO VHT IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	9.89%	Shs Outstand	40.69M	Perf Week	-3.78%
Market Cap	595.78M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-2.46%	Shs Float	37.01M	Perf Month	-6.81%
Income	-43.34M	PEG	-	EPS next Q	-0.31	Inst Own	88.55%	Short Float	7.01%	Perf Quarter	-28.20%
Sales	138.89M	P/S	4.29	EPS this Y	12.54%	Inst Trans	-0.55%	Short Ratio	6.02	Perf Half Y	-12.06%
Book/sh	4.16	P/B	3.49	EPS next Y	22.60%	ROA	-22.34%	Short Interest	2.59M	Perf Year	-35.80%
Cash/sh	4.04	P/C	3.59	EPS next 5Y	8.90%	ROE	-32.38%	52W Range	14.12 - 29.51	Perf YTD	-30.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.47%	ROI	-20.94%	52W High	-50.83%	Beta	1.25
Dividend TTM	-	Quick Ratio	8.15	Sales past 5Y	20.39%	Gross Margin	78.78%	52W Low	2.76%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	9.01	EPS Y/Y TTM	36.78%	Oper. Margin	-33.79%	RSI (14)	38.59	Volatility	4.51% 3.92%
Employees	344	Debt/Eq	0.23	Sales Y/Y TTM	30.52%	Profit Margin	-31.20%	Recom	1.00	Target Price	26.22
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	16.22%	Payout	-	Rel Volume	0.60	Prev Close	14.26
Sales Surprise	2.49%	EPS Surprise	2.91%	Sales Q/Q	21.61%	Earnings	May 06 AMC	Avg Volume	430.62K	Price	14.51
SMA20	-4.89%	SMA50	-11.67%	SMA200	-25.04%	Trades		Volume	257,161	Change	1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Piper Sandler	Overweight	$25
Oct-12-22	Initiated	Jefferies	Buy	$20
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$34
Jun-08-21	Initiated	Citigroup	Buy	$40
Mar-09-21	Reiterated	Needham	Buy	$35 → $34
Dec-16-20	Reiterated	Needham	Buy	$28 → $35
Aug-04-20	Reiterated	Needham	Buy	$22 → $24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$25
May-05-20	Reiterated	Needham	Buy	$27 → $22
Feb-19-20	Initiated	Needham	Buy	$27
Jan-08-20	Initiated	SunTrust	Buy	$27
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-12-18	Initiated	Morgan Stanley	Overweight	$24
Nov-12-18	Initiated	JMP Securities	Mkt Outperform	$27
Nov-12-18	Initiated	Canaccord Genuity	Buy	$25
Nov-12-18	Initiated	BofA/Merrill	Buy	$23

Show Previous Ratings

Apr-29-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
09:00AM	SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024 (GlobeNewswire)
Apr-15-24 04:09PM	SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire)
Mar-04-24 04:09PM	SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024 (GlobeNewswire)
Feb-27-24 06:49AM	Q4 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -13.53%
05:38PM	Loading…
Feb-26-24 05:38PM	Si-Bone: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	SI-BONE Inc (SIBN) Reports Record Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:09PM	SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance (GlobeNewswire)
Feb-19-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:09PM	SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024 (GlobeNewswire)
Jan-30-24 08:30AM	SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:30AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023 (GlobeNewswire) -7.06%
Jan-05-24 09:02AM	SI-BONE Inc Director Davis Timothy E JR Sells 9,900 Shares (GuruFocus.com)
Nov-30-23 09:30AM	Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
07:03AM	Loading…
Nov-21-23 07:03AM	Insider Sell: President, Commercial Ops Anthony Recupero Sells 8,457 Shares of SI-BONE Inc (SIBN) (GuruFocus.com)
Nov-14-23 04:09PM	SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 (GlobeNewswire) +9.47%
Nov-07-23 11:08AM	SI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:00AM	Q3 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:38PM	Si-Bone: Q3 Earnings Snapshot (Associated Press Finance)
05:01PM	SI-BONE Inc (SIBN) Reports Record Q3 2023 Financial Results, Raises Annual Guidance (GuruFocus.com)
04:09PM	SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance (GlobeNewswire)
Nov-01-23 04:09PM	SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023 (GlobeNewswire)
Oct-16-23 04:09PM	SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Oct-09-23 12:00PM	Si-Bone (SIBN) Upgraded to Buy: Here's Why (Zacks)
Sep-08-23 09:40AM	Has SiBone (SIBN) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-06-23 09:55AM	Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect? (Zacks)
Sep-05-23 04:09PM	SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods (GlobeNewswire)
Aug-29-23 04:09PM	SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023 (GlobeNewswire)
Aug-09-23 10:07AM	SI-BONE, Inc. (NASDAQ:SIBN) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:23AM	Loading…
Aug-08-23 06:23AM	Q2 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -11.17%
Aug-07-23 05:20PM	Si-Bone: Q2 Earnings Snapshot (AP Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance (GlobeNewswire)
Jul-19-23 04:09PM	SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023 (GlobeNewswire)
Jul-17-23 04:09PM	SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire)
Jul-06-23 10:00AM	Best Momentum Stocks to Buy for July 6th (Zacks)
May-29-23 10:15AM	Despite shrinking by US$86m in the past week, SI-BONE (NASDAQ:SIBN) shareholders are still up 69% over 1 year (Simply Wall St.)
May-24-23 04:09PM	SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023 (GlobeNewswire)
May-04-23 10:29PM	SI-BONE Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:09PM	SI-BONE Announces Launch of Public Offering of Common Stock (GlobeNewswire)
12:00PM	Si-Bone (SIBN) Upgraded to Buy: Here's What You Should Know (Zacks)
May-02-23 02:12PM	Why Shares of Si-Bone Jumped Tuesday (Motley Fool) +7.17%
10:33AM	Q1 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-23 06:05PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	SI-BONE, Inc. Reports Financial Results for the First Quarter 2023 and Increases Annual Guidance (GlobeNewswire)
Apr-24-23 04:09PM	SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference (GlobeNewswire)
04:50AM	Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength? (Zacks)
Apr-18-23 07:10AM	Why We're Not Concerned About SI-BONE, Inc.'s (NASDAQ:SIBN) Share Price (Simply Wall St.)
Apr-10-23 04:09PM	SI-BONE To Report First Quarter 2023 Financial Results on May 1, 2023 (GlobeNewswire)
Mar-10-23 06:56AM	SI-BONE, Inc. (NASDAQ:SIBN) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.61%
Mar-01-23 05:26AM	SI-BONE Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Feb-28-23 04:13PM	Analysts Remain Bullish On SI-BONE, Forecast Q4's Strength To Continue In 2023 (Benzinga) +16.74%
09:52AM	Q4 2022 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:35PM	Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:09PM	SI-BONE, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Issues 2023 Guidance (GlobeNewswire)
Feb-20-23 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-06-23 04:09PM	SI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023 (GlobeNewswire)
Jan-09-23 09:00AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022 (GlobeNewswire) +14.08%
Jan-03-23 04:09PM	SI-BONE to Host a Virtual Fireside Chat at the 25th Annual Needham Growth Conference (GlobeNewswire)
Dec-27-22 08:30AM	SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite® Implant System (GlobeNewswire)
Dec-01-22 09:01AM	Shareholders in SI-BONE (NASDAQ:SIBN) are in the red if they invested a year ago (Simply Wall St.)
Nov-07-22 05:35PM	Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance (GlobeNewswire)
Oct-31-22 10:00AM	Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-17-22 04:04PM	SI-BONE To Report Third Quarter 2022 Financial Results on November 7, 2022 (GlobeNewswire) +7.65%
Sep-11-22 09:22AM	Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt? (Simply Wall St.)
Aug-29-22 09:55AM	Does Si-Bone (SIBN) Have the Potential to Rally 42% as Wall Street Analysts Expect? (Zacks)
Aug-23-22 08:02AM	SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-22 09:55AM	Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade (Zacks)
Aug-08-22 05:35PM	Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022 (GlobeNewswire)
Aug-04-22 10:00AM	Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Aug-01-22 10:01AM	Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-19-22 01:34AM	Germany rejects Russian rationale for gas supply cuts, while Gazprom declares force majuere on some buyers (MarketWatch)
Jul-18-22 08:00AM	SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022 (GlobeNewswire) +6.00%
08:00AM	SI-BONE To Present at The Canaccord Genuity 42nd Annual Growth Conference 2022 (GlobeNewswire)
Jun-13-22 08:00AM	SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System (GlobeNewswire)
Jun-12-22 09:15AM	Shareholders in SI-BONE (NASDAQ:SIBN) are in the red if they invested a year ago (Simply Wall St.)
May-31-22 08:00AM	SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology (GlobeNewswire)
May-15-22 08:14PM	Morgan Stanley Says These 3 Stocks Could Surge Over 60% From Current Levels (TipRanks)
May-09-22 05:25PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -12.62%
04:02PM	SI-BONE, Inc. Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 05:35PM	ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.31%
May-04-22 06:25PM	Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-22 03:00PM	Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline (Zacks)
Apr-19-22 08:00AM	SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment (GlobeNewswire) +9.38%
Apr-18-22 04:03PM	SI-BONE To Present at BofA Securities 2022 Healthcare Conference (GlobeNewswire) -5.93%
08:00AM	SI-BONE To Report First Quarter 2022 Financial Results on May 9, 2022 (GlobeNewswire)
Apr-04-22 01:35PM	Is SI-BONE (NASDAQ:SIBN) A Risky Investment? (Simply Wall St.) -5.01%
Mar-16-22 06:00AM	Western oilfield services companies stay the course in Russia (Financial Times)
Feb-28-22 04:02PM	SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance (GlobeNewswire)
Feb-01-22 08:00AM	SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 (GlobeNewswire)
Jan-10-22 07:00AM	SI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021 (GlobeNewswire) +9.16%
Jan-03-22 12:43PM	Shareholders in SI-BONE (NASDAQ:SIBN) are in the red if they invested a year ago (Simply Wall St.)
Dec-27-21 04:03PM	SI-BONE to participate in 24th Annual Needham Virtual Growth Conference (GlobeNewswire)
Dec-25-21 01:38PM	Usgi Emerging Europe Fund Buys PJSC Lukoil, Rosneft Oil Co, Mining and Metallurgical Company ... (GuruFocus.com)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-23-21 01:38PM	MainStay VP Small Cap Growth Portfolio Buys Option Care Health Inc, Leslies Inc, Kratos Defense ... (GuruFocus.com)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-13-21 04:02PM	SI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence Street Opinion, and New Coverage Policies from Arkansas Blue Cross Blue Shield and Walmart Plans from BlueAdvantage Administrators of Arkansas (GlobeNewswire)

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RECUPERO ANTHONY J	President, Commercial Ops	Apr 03 '24	Sale	15.63	920	14,379	251,533	Apr 04 07:59 PM
RECUPERO ANTHONY J	President, Commercial Ops	Apr 02 '24	Sale	15.50	3,307	51,272	252,453	Apr 04 07:59 PM
Maheshwari Anshul	Chief Financial Officer	Apr 02 '24	Sale	15.45	2,425	37,474	205,516	Apr 04 07:59 PM
RECUPERO ANTHONY J	President, Commercial Ops	Mar 13 '24	Sale	16.82	3,330	56,023	255,760	Mar 14 05:46 PM
Nishimura Mika	Director	Mar 13 '24	Sale	16.22	2,500	40,550	19,350	Mar 14 05:45 PM
FRANCIS LAURA	Chief Executive Officer	Feb 16 '24	Sale	20.95	38,587	808,591	501,476	Feb 21 04:22 PM
RECUPERO ANTHONY J	President, Commercial Ops	Feb 16 '24	Sale	20.95	7,822	163,910	259,090	Feb 21 04:20 PM
Maheshwari Anshul	Chief Financial Officer	Feb 16 '24	Sale	20.96	7,336	153,726	207,941	Feb 21 04:20 PM
DUNN JEFFREY W	Director	Feb 16 '24	Sale	20.95	4,160	87,173	40,223	Feb 21 04:21 PM
DUNN JEFFREY W	Director	Feb 02 '24	Sale	20.30	335	6,799	44,383	Feb 05 07:53 PM
Davis Timothy E JR	Director	Jan 02 '24	Option Exercise	3.24	21,111	68,400	43,472	Jan 09 06:01 PM
Davis Timothy E JR	Director	Jan 02 '24	Sale	20.93	9,900	207,221	22,361	Jan 04 06:08 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jan 02 '24	Sale	20.93	1,936	40,511	198,903	Jan 04 06:07 PM
Maheshwari Anshul	Chief Financial Officer	Jan 02 '24	Sale	20.92	1,470	30,758	147,268	Jan 04 06:06 PM
RECUPERO ANTHONY J	President, Commercial Ops	Nov 17 '23	Sale	17.78	2,996	53,274	200,839	Nov 20 06:44 PM
DUNN JEFFREY W	Director	Nov 16 '23	Sale	17.69	7,965	140,898	44,718	Nov 20 06:45 PM
RECUPERO ANTHONY J	President, Commercial Ops	Nov 16 '23	Sale	17.69	5,461	96,582	203,835	Nov 20 06:44 PM
Maheshwari Anshul	Chief Financial Officer	Nov 16 '23	Sale	17.59	1,733	30,478	148,738	Nov 20 06:43 PM
DUNN JEFFREY W	Director	Nov 02 '23	Sale	17.52	406	7,113	52,683	Nov 06 07:12 PM
DUNN JEFFREY W	Director	Oct 02 '23	Option Exercise	4.32	20,000	86,400	89,645	Oct 04 05:53 PM
DUNN JEFFREY W	Director	Oct 02 '23	Sale	21.19	20,000	423,738	69,645	Oct 04 05:53 PM
RECUPERO ANTHONY J	President, Commercial Ops	Oct 02 '23	Sale	21.16	1,712	36,222	209,296	Oct 04 05:52 PM
Maheshwari Anshul	Chief Financial Officer	Oct 02 '23	Sale	21.15	1,244	26,310	150,471	Oct 04 05:51 PM
DUNN JEFFREY W	Director	Sep 01 '23	Option Exercise	4.32	20,000	86,400	89,645	Sep 06 07:19 PM
DUNN JEFFREY W	Director	Sep 01 '23	Sale	22.61	20,000	452,192	69,645	Sep 06 07:19 PM
RECUPERO ANTHONY J	President, Commercial Ops	Aug 17 '23	Sale	21.07	2,997	63,147	211,008	Aug 18 04:13 PM
FRANCIS LAURA	Chief Executive Officer	Aug 16 '23	Sale	20.96	9,012	188,900	437,039	Aug 18 04:12 PM
DUNN JEFFREY W	Director	Aug 16 '23	Sale	20.99	7,964	167,126	69,645	Aug 18 04:11 PM
RECUPERO ANTHONY J	President, Commercial Ops	Aug 16 '23	Sale	20.98	5,485	115,097	214,005	Aug 18 04:13 PM
Maheshwari Anshul	Chief Financial Officer	Aug 16 '23	Sale	20.98	1,733	36,363	151,715	Aug 18 04:13 PM
DUNN JEFFREY W	Director	Aug 11 '23	Option Exercise	4.32	20,000	86,400	97,609	Aug 15 05:17 PM
DUNN JEFFREY W	Director	Aug 11 '23	Sale	21.48	20,000	429,634	77,609	Aug 15 05:17 PM
Freund John Gordon	Director	Aug 09 '23	Sale	20.54	30,000	616,197	103,899	Aug 11 04:24 PM
DUNN JEFFREY W	Director	Aug 02 '23	Sale	25.08	406	10,181	77,609	Aug 03 07:00 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jul 03 '23	Sale	26.68	1,712	45,684	219,490	Jul 05 06:11 PM
Maheshwari Anshul	Chief Financial Officer	Jul 03 '23	Sale	26.70	1,244	33,219	153,448	Jul 05 06:13 PM
HILLEMAN JERYL L	Director	Jun 20 '23	Sale	28.00	2,081	58,268	15,349	Jun 20 06:02 PM
HILLEMAN JERYL L	Director	Jun 15 '23	Sale	28.74	2,081	59,808	17,430	Jun 20 06:02 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jun 15 '23	Sale	28.59	48	1,372	221,202	Jun 20 06:04 PM
Maheshwari Anshul	Chief Financial Officer	Jun 07 '23	Sale	28.00	3,272	91,616	154,692	Jun 09 05:11 PM
RECUPERO ANTHONY J	President, Commercial Ops	May 17 '23	Sale	24.91	2,997	74,644	221,250	May 18 05:37 PM
FRANCIS LAURA	Chief Executive Officer	May 16 '23	Sale	24.84	9,009	223,779	445,836	May 18 05:36 PM
DUNN JEFFREY W	Director	May 16 '23	Sale	24.83	7,962	197,708	77,204	May 18 05:35 PM
RECUPERO ANTHONY J	President, Commercial Ops	May 16 '23	Sale	24.80	5,459	135,405	222,356	May 18 05:37 PM
Maheshwari Anshul	Chief Financial Officer	May 16 '23	Sale	24.48	3,624	88,705	157,964	May 18 05:34 PM
DUNN JEFFREY W	Director	May 09 '23	Option Exercise	3.42	272,753	932,815	357,919	May 10 07:52 PM
DUNN JEFFREY W	Director	May 09 '23	Sale	22.00	272,753	6,000,566	85,166	May 10 07:52 PM

Open in Screener

NVCR

NovoCure Ltd

May 01 • 04:00PM ET

12.74

Dollar change +0.50
Percentage change 4.08	%

Healthcare • Medical Devices • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK IBB IHI SCHA IWP VHT IWF

Index	-	P/E	-	EPS (ttm)	-1.95	Insider Own	10.09%	Shs Outstand	107.08M	Perf Week	3.24%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-1.83	Insider Trans	-0.10%	Shs Float	96.75M	Perf Month	-11.47%
Income	-207.04M	PEG	-	EPS next Q	-0.42	Inst Own	83.81%	Short Float	6.24%	Perf Quarter	-8.48%
Sales	509.34M	P/S	2.69	EPS this Y	9.89%	Inst Trans	2.97%	Short Ratio	4.73	Perf Half Y	-2.45%
Book/sh	3.39	P/B	3.76	EPS next Y	-4.31%	ROA	-17.71%	Short Interest	6.04M	Perf Year	-80.96%
Cash/sh	8.48	P/C	1.50	EPS next 5Y	-	ROE	-51.52%	52W Range	10.87 - 83.60	Perf YTD	-14.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.97%	ROI	-21.60%	52W High	-84.76%	Beta	0.49
Dividend TTM	-	Quick Ratio	5.56	Sales past 5Y	17.16%	Gross Margin	74.91%	52W Low	17.20%	ATR (14)	0.72
Dividend Ex-Date	-	Current Ratio	5.78	EPS Y/Y TTM	-120.47%	Oper. Margin	-45.63%	RSI (14)	45.65	Volatility	4.81% 5.08%
Employees	1453	Debt/Eq	1.67	Sales Y/Y TTM	-5.30%	Profit Margin	-40.65%	Recom	2.43	Target Price	25.86
Option/Short	Yes / Yes	LT Debt/Eq	1.64	EPS Q/Q	-23.90%	Payout	-	Rel Volume	1.01	Prev Close	12.24
Sales Surprise	-0.01%	EPS Surprise	13.69%	Sales Q/Q	4.17%	Earnings	May 02 BMO	Avg Volume	1.28M	Price	12.74
SMA20	-2.50%	SMA50	-10.84%	SMA200	-26.77%	Trades		Volume	1,288,479	Change	4.08%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform	$159 → $154

Show Previous Ratings

Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-24-24 10:45AM	Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 (Business Wire)
Apr-05-24 07:00AM	Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 (Business Wire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade (Zacks)
07:00AM	Loading…
07:00AM	Novocure to Report First Quarter 2024 Financial Results (Business Wire)
Mar-30-24 06:34AM	Why NovoCure Stock Soared 18.3% This Week (Motley Fool)
Mar-28-24 11:50AM	Why Novocure Stock Is Jumping Today (Motley Fool) +6.76%
05:01AM	NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 04:08PM	Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish (Investor's Business Daily) +12.01%
09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
09:16AM	Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment (Investor's Business Daily)
07:14AM	UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:12AM	Novocure's device shown to slow cancer progression in the brain in trial (Reuters)
07:05AM	Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:00AM	Loading…
07:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-13-24 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Business Wire)
Feb-23-24 11:43AM	NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 12:15PM	NovoCure (NVCR) Q4 2023 Earnings Call Transcript (Motley Fool)
08:25AM	NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:36AM	NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:23AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Business Wire)
Jan-19-24 07:46AM	Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength? (Zacks)
Jan-18-24 02:19PM	Why Is Cancer Focused Novocure Stock Trading Higher Today? (Benzinga) +16.75%
07:00AM	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Business Wire)
Jan-11-24 09:55AM	Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know (Zacks)
Jan-09-24 07:00AM	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Business Wire)
Jan-08-24 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Business Wire) +11.61%
04:05PM	Loading…
Jan-04-24 04:05PM	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Business Wire)
Dec-27-23 07:00AM	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.20%
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey)
Dec-04-23 04:46PM	The Top and Bottom Stocks of 2023 (Investopedia)
Nov-28-23 10:51AM	Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts (InvestorPlace)
07:30AM	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Business Wire)
Nov-21-23 07:00AM	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-23 09:09AM	11 Best Undervalued UK Stocks To Buy Now (Insider Monkey) +12.48%
Nov-10-23 08:00AM	Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting (Business Wire)
Nov-03-23 06:45AM	Is Novocure Stock a Buy? (Motley Fool)
Oct-30-23 02:04AM	The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-28-23 08:39AM	NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 04:35PM	Why Novocure Stock Was Sick Today (Motley Fool) -7.53%
11:00AM	NovoCure (NVCR) Q3 2023 Earnings Call Transcript (Motley Fool)
08:52AM	NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:24AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-15-23 06:05PM	Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 (Business Wire)
Oct-12-23 08:00AM	Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program (Business Wire) -5.53%
Oct-02-23 07:00AM	Novocure to Report Third Quarter 2023 Financial Results (Business Wire)
Sep-29-23 05:00PM	Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting (Business Wire)
Sep-18-23 11:47AM	Should You Hold NovoCure Limited (NVCR)? (Insider Monkey)
Sep-08-23 04:01PM	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Business Wire)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Sep-04-23 09:30AM	Down 31% in 1 Day, What's Next for NovoCure Stock? (Motley Fool)
Aug-31-23 06:52PM	Why Novocure Stock Fell 24.4% This Week (Motley Fool)
09:55AM	Is NovoCure's Stock Headed for a Free Fall? (Motley Fool)
Aug-29-23 06:31PM	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Business Wire) +8.84%
Aug-28-23 05:15PM	Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal (Investopedia) -37.50%
04:08PM	Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails (Investor's Business Daily)
02:19PM	Novocure Plummets 35% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
12:21PM	Why NovoCure Stock Is Crashing Today (Motley Fool)
12:16PM	3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023 (AP Finance)
12:10PM	NovoCure Ltd (NVCR): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:47AM	NovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth Exploration (GuruFocus.com)
09:34AM	Midday movers: 3M, XPeng, Hawaiian Electric Industries and more (Investing.com)
07:27AM	UPDATE 1-Novocure's cancer therapy fails to meet main goal in late-stage trial (Reuters)
07:10AM	Novocure says its ovarian cancer therapy did not meet main goal in late-stage trial (Reuters)
07:00AM	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Business Wire)
Aug-25-23 08:20AM	Could NovoCure Stock Help You Become a Millionaire? (Motley Fool)
07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire)
Aug-15-23 09:30AM	Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod (Zacks)
Aug-13-23 05:49PM	15 Worst Performing Healthcare Stocks in 2023 (Insider Monkey)
Aug-09-23 10:45AM	2 Incredibly Cheap Growth Stocks to Buy in August (Motley Fool) +7.13%
05:10AM	Is NovoCure Stock a Buy Now? (Motley Fool)
Aug-08-23 04:11PM	Why Novocure Was a Healthy Stock Today (Motley Fool)
10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 03:54PM	10 Oversold NASDAQ Stocks to Buy (Insider Monkey)
Jul-27-23 06:56PM	Why Novocure Stock Tumbled by Nearly 16% Today (Motley Fool) -15.89%
11:30AM	NovoCure (NVCR) Q2 2023 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:07AM	NovoCure: Q2 Earnings Snapshot (AP Finance)
07:00AM	Novocure Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-25-23 10:01AM	Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline (Zacks)
Jul-21-23 08:00AM	Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer (Business Wire)
Jul-06-23 01:17PM	Here's Why Novocure Stock Dropped 42% in June (Motley Fool)
Jul-03-23 08:00AM	Novocure to Report Second Quarter 2023 Financial Results (Business Wire)
Jun-12-23 09:30AM	3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon (InvestorPlace)
05:39AM	This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street (Motley Fool)
Jun-09-23 09:45AM	Novocure Breaks a Major Support Zone: What Now? (TheStreet.com) -6.02%
Jun-07-23 11:05AM	Why Shares of Zai Lab Are Dropping Wednesday (Motley Fool)
Jun-06-23 04:02PM	Novocure Crashes 43% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment (Investor's Business Daily) -43.04%
04:01PM	Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops +40% (Investor's Business Daily)
03:40PM	Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts (Benzinga)
02:48PM	These 2 Nasdaq Stocks Are Plunging. Here's Why (Motley Fool)
11:50AM	Why NovoCure Stock Is Crashing Today (Motley Fool)
10:31AM	Novocure Crashes Almost 30% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment (Investor's Business Daily)
08:31AM	UPDATE 2-Novocure's lung cancer device extends survival in late-stage study (Reuters)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 04 '24	Sale	16.01	1,217	19,484	251,235	Mar 05 04:09 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 04 '24	Sale	16.01	840	13,448	160,098	Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 01 '24	Sale	16.03	2,107	33,769	252,452	Mar 05 04:09 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 01 '24	Sale	16.03	1,679	26,909	160,938	Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Feb 28 '24	Sale	16.14	2,303	37,177	254,559	Feb 29 04:28 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '24	Sale	16.14	2,078	33,545	162,617	Feb 29 04:38 PM
Shah Pritesh	Chief Growth Officer	Nov 07 '23	Sale	12.65	382	4,832	124,511	Nov 08 04:22 PM
Cordova Ashley	Chief Financial Officer	Nov 02 '23	Option Exercise	11.46	175	2,006	117,618	Nov 02 04:20 PM
Cordova Ashley	Chief Financial Officer	Oct 31 '23	Option Exercise	9.58	17,793	170,447	117,443	Nov 02 04:20 PM
Cordova Ashley	Chief Financial Officer	Sep 01 '23	Sale	21.82	883	19,265	99,650	Sep 05 04:24 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 01 '23	Sale	21.82	294	6,414	209,825	Sep 05 04:24 PM
Shah Pritesh	Chief Growth Officer	Sep 01 '23	Sale	21.82	273	5,956	124,893	Sep 05 04:23 PM
Cordova Ashley	Chief Financial Officer	Aug 02 '23	Sale	30.25	1,144	34,607	100,533	Aug 04 04:02 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SIBN

SI-BONE Inc

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience